3 ms·
The problem with this sort of analysis is that the logistical concerns of shipping vaccine doses are immense. For one thing, single "doses" don't exist - both P
by XorNot 5y ago
The problem with this sort of analysis is that the logistical concerns of shipping vaccine doses are immense. For one thing, single "doses" don't exist - both Pfizer and Astrazeneca are distributed in multi-dose vials. If you as a patient are given a dose at the end of the day, and no one else is available right then and there to receive it, then that's anywhere from 1 to 5 doses which are literally thrown away.
As vaccination rates rise, the mere existence of vaccine stocks in countries with high vaccination rates means doses will be wasted - i.e. keeping the bare minimum on hand to vaccinate people as they need it means we have quite a lot of surplus doses which will otherwise definitely be wasted.
Hence the analysis of boosters: if there's any benefit at all to high risk groups (i.e. healthcare providers who overwhelmingly now were vaccinated about 8 months ago), then that's a productive use of local vaccine capacity which has to exist in some form (i.e. new people are hitting "vaccine recommended" age every day).
- swader999 5y agoAnd this virus mutates which also limits the shelf life.